We admire the mountains of Austria with the co-founder of Curie.Bio, a founder-friendly fund that now manages $1.25B and backs 38 portfolio companies.We discuss Curie.Bio’s track record, with its most advanced portfolio candidate Forward Therapeutics in Phase I.We also talk about major bottom-up successes including argenx, Ascendis and Genmab, and how life sciences investing differs from tech investing.Christoph also explains his ‘rebel’ mindset and why founders shouldn’t accept the status quo.

---This episode is brought to you by Avance, where European biotech turns for trusted financial advice. Learn more at https://bit.ly/flot-avance---

⭐️ ABOUT THE SPEAKER

Christoph co-founded of Curie.Bio in 2022, after serving as Partner at Third Rock Ventures for 6 years. He also had leading roles at Blueprint Medicines for ten years, and at MOMA Therapeutics for one year.He has also been an Adjunct Associate Professor at Johns Hopkins University for more than 20 years, with past roles at Celsius Therapeutics, Sanofi, and Novartis. 🔗 LINKS MENTIONED

📜 TRANSCRIPT

Read the full transcript here: https://flot.bio/episode/christoph-lengauer-curiebio-biotech-founders/


📖 BLOGS BASED ON THIS EPISODE:


💸 DONATE

We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme

⭐️ SPONSORSHIP

Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!

🫶 FOLLOW US

🙏 LIKE/FOLLOW/REVIEW

Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.

🎙️ ABOUT FLOT.BIO

Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.⏰ TIMESTAMPS

  • [00:00:00] Intro
  • [00:03:05] Curie.Bio: 38 portfolio companies in just three years
  • [00:09:29] The four buckets of biotech venture capital
  • [00:15:42] Why life sciences investing is harder than tech investing
  • [00:28:28] Searching for European biotech innovation
  • [00:38:00] Founder-friendly equity shares
  • [00:55:15] argenx, Genmab and Ascendis: Bottom-up biotech successes
  • [01:03:37] Blueprint Medicines: From struggle to a $9B sale
  • [01:09:03] Christoph Lengauer the disruptor
  • [01:13:37] Quick-fire questions

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Flot.bio. Innehållet i podden är skapat av Flot.bio och inte av, eller tillsammans med, Poddtoppen.